GenesisCare Imoncology on Muck Rack

GenesisCare Imoncology

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with GenesisCare

Contact GenesisCare, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CONVERTed or not: what are the barriers to implementing the evidence?

|
By Matthew Katz, Richard Simcock, Castalia Fernández, GenesisCare Imoncology
| The Lancet Verified
We read with interest the results of CONVERT, the multi-institutional phase 3 randomised trial comparing radiotherapy dose schedules for limited-stage small-cell lung cancer by Corinne Faivre-Finn and colleagues.1 Early results from this important clinical trial support the findings from Intergroup 0096 (INT 0096), which established twice-daily radiotherapy as the standard of care for limited-stage small-cell lung cancer in 1999.2The results of CONVERT were discussed with Dr Faivre-Finn...
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified